Cargando…

Declined Serum Resolvin D1 Levels to Predict Severity and Prognosis of Human Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study

BACKGROUND: Resolvin D1 (RvD1) possesses anti-inflammatory properties and may be neuroprotective. This study was designed to ascertain the potential role of serum RvD1 in the evaluation of aSAH severity and prognosis of human aneurysmal subarachnoid hemorrhage (aSAH). METHODS: In this prospective ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Danfeng, Jiang, Fengfeng, Xu, Wei, He, Pingyou, Chen, Feng, Liu, Xiaobo, Bao, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314781/
https://www.ncbi.nlm.nih.gov/pubmed/37396872
http://dx.doi.org/10.2147/NDT.S417630
_version_ 1785067382346088448
author Yu, Danfeng
Jiang, Fengfeng
Xu, Wei
He, Pingyou
Chen, Feng
Liu, Xiaobo
Bao, Xiang
author_facet Yu, Danfeng
Jiang, Fengfeng
Xu, Wei
He, Pingyou
Chen, Feng
Liu, Xiaobo
Bao, Xiang
author_sort Yu, Danfeng
collection PubMed
description BACKGROUND: Resolvin D1 (RvD1) possesses anti-inflammatory properties and may be neuroprotective. This study was designed to ascertain the potential role of serum RvD1 in the evaluation of aSAH severity and prognosis of human aneurysmal subarachnoid hemorrhage (aSAH). METHODS: In this prospective observational study, serum RvD1 levels were measured in 123 patients with aSAH and in 123 healthy volunteers. Six-month neurological function was assessed using extended Glasgow outcome scale (GOSE). A prognostic prediction model was appraised using a series of evaluative tools, such as a nomogram, receiver operating characteristic (ROC) curve, decision curve, calibration curve, restricted cubic spline, and Hosmer-Lemeshow goodness of fit statistics. RESULTS: Serum RvD1 levels were markedly lower in patients than in controls (median, 0.54 versus 1.47 ng/mL; P<0.001). Serum RvD1 levels were independently correlated with Hunt-Hess scores (beta, −0.154; 95% confidence interval [CI], −0.198--0.109; VIF, 1.769; P=0.001), modified Fisher scores (beta, −0.066; 95% CI, −0.125--0.006; VIF, 1.567; P=0.031) and 6-month GOSE scores (beta, 1.864; 95% CI, 0.759–2.970; VIF, 1.911; P=0.001) and were independently predictive of a poor prognosis (GOSE scores of 1–4) (odds ratio, 0.137; 95% CI, 0.023–0.817; P=0.029). Serum RvD1 levels significantly distinguished the risk of a worse prognosis, with an area under the ROC curve of 0.750 (95% CI, 0.664–0.824). Using the Youden method, serum RvD1 levels < 0.6 ng/mL was effective in predicting worse prognosis with 84.1% sensitivity and 62.0% specificity. Moreover, the model containing serum RvD1 levels, Hunt-Hess scores and modified Fisher scores was efficient, reliable and beneficial in prognostic prediction using a series of the afore-mentioned evaluative tools. CONCLUSION: A decline in serum RvD1 levels following aSAH is closely correlated with illness severity and independently predicts a worse outcome in patients with aSAH, implying that serum RvD1, as a prognostic biomarker of aSAH, may be of clinical value in aSAH.
format Online
Article
Text
id pubmed-10314781
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-103147812023-07-02 Declined Serum Resolvin D1 Levels to Predict Severity and Prognosis of Human Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study Yu, Danfeng Jiang, Fengfeng Xu, Wei He, Pingyou Chen, Feng Liu, Xiaobo Bao, Xiang Neuropsychiatr Dis Treat Original Research BACKGROUND: Resolvin D1 (RvD1) possesses anti-inflammatory properties and may be neuroprotective. This study was designed to ascertain the potential role of serum RvD1 in the evaluation of aSAH severity and prognosis of human aneurysmal subarachnoid hemorrhage (aSAH). METHODS: In this prospective observational study, serum RvD1 levels were measured in 123 patients with aSAH and in 123 healthy volunteers. Six-month neurological function was assessed using extended Glasgow outcome scale (GOSE). A prognostic prediction model was appraised using a series of evaluative tools, such as a nomogram, receiver operating characteristic (ROC) curve, decision curve, calibration curve, restricted cubic spline, and Hosmer-Lemeshow goodness of fit statistics. RESULTS: Serum RvD1 levels were markedly lower in patients than in controls (median, 0.54 versus 1.47 ng/mL; P<0.001). Serum RvD1 levels were independently correlated with Hunt-Hess scores (beta, −0.154; 95% confidence interval [CI], −0.198--0.109; VIF, 1.769; P=0.001), modified Fisher scores (beta, −0.066; 95% CI, −0.125--0.006; VIF, 1.567; P=0.031) and 6-month GOSE scores (beta, 1.864; 95% CI, 0.759–2.970; VIF, 1.911; P=0.001) and were independently predictive of a poor prognosis (GOSE scores of 1–4) (odds ratio, 0.137; 95% CI, 0.023–0.817; P=0.029). Serum RvD1 levels significantly distinguished the risk of a worse prognosis, with an area under the ROC curve of 0.750 (95% CI, 0.664–0.824). Using the Youden method, serum RvD1 levels < 0.6 ng/mL was effective in predicting worse prognosis with 84.1% sensitivity and 62.0% specificity. Moreover, the model containing serum RvD1 levels, Hunt-Hess scores and modified Fisher scores was efficient, reliable and beneficial in prognostic prediction using a series of the afore-mentioned evaluative tools. CONCLUSION: A decline in serum RvD1 levels following aSAH is closely correlated with illness severity and independently predicts a worse outcome in patients with aSAH, implying that serum RvD1, as a prognostic biomarker of aSAH, may be of clinical value in aSAH. Dove 2023-06-27 /pmc/articles/PMC10314781/ /pubmed/37396872 http://dx.doi.org/10.2147/NDT.S417630 Text en © 2023 Yu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yu, Danfeng
Jiang, Fengfeng
Xu, Wei
He, Pingyou
Chen, Feng
Liu, Xiaobo
Bao, Xiang
Declined Serum Resolvin D1 Levels to Predict Severity and Prognosis of Human Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study
title Declined Serum Resolvin D1 Levels to Predict Severity and Prognosis of Human Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study
title_full Declined Serum Resolvin D1 Levels to Predict Severity and Prognosis of Human Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study
title_fullStr Declined Serum Resolvin D1 Levels to Predict Severity and Prognosis of Human Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study
title_full_unstemmed Declined Serum Resolvin D1 Levels to Predict Severity and Prognosis of Human Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study
title_short Declined Serum Resolvin D1 Levels to Predict Severity and Prognosis of Human Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study
title_sort declined serum resolvin d1 levels to predict severity and prognosis of human aneurysmal subarachnoid hemorrhage: a prospective cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314781/
https://www.ncbi.nlm.nih.gov/pubmed/37396872
http://dx.doi.org/10.2147/NDT.S417630
work_keys_str_mv AT yudanfeng declinedserumresolvind1levelstopredictseverityandprognosisofhumananeurysmalsubarachnoidhemorrhageaprospectivecohortstudy
AT jiangfengfeng declinedserumresolvind1levelstopredictseverityandprognosisofhumananeurysmalsubarachnoidhemorrhageaprospectivecohortstudy
AT xuwei declinedserumresolvind1levelstopredictseverityandprognosisofhumananeurysmalsubarachnoidhemorrhageaprospectivecohortstudy
AT hepingyou declinedserumresolvind1levelstopredictseverityandprognosisofhumananeurysmalsubarachnoidhemorrhageaprospectivecohortstudy
AT chenfeng declinedserumresolvind1levelstopredictseverityandprognosisofhumananeurysmalsubarachnoidhemorrhageaprospectivecohortstudy
AT liuxiaobo declinedserumresolvind1levelstopredictseverityandprognosisofhumananeurysmalsubarachnoidhemorrhageaprospectivecohortstudy
AT baoxiang declinedserumresolvind1levelstopredictseverityandprognosisofhumananeurysmalsubarachnoidhemorrhageaprospectivecohortstudy